Restricted Content
Lately headlines involving pharmaceuticals have become more commonplace — a few recent stories from the OPEN MINDS Weekly News Wire reminded me of the many new developments in this area. Most recently, these developments focused on the opioid crisis (see FDA Approves Six-Month Implant For Opioid Addiction Treatment), new research incubators (see Janssen Launches New Research Platforms For Disease Prevention . . .
